NASDAQ:VIRI
Virios Therapeutics, Inc.
- Stock
Last Close
0.39
17/05 20:00
Market Cap
7.90M
Beta: 1.93
Volume Today
258.46K
Avg: 2.87M
PE Ratio
−1.08
PFCF: −1.11
Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|
average inventory | -162 - | -162 0% | |||||
average payables | 90.54K - | 202.16K 123.29% | 361.38K 78.76% | 463.51K 28.26% | 286.58K 38.17% | ||
average receivables | 559.50 - | 554.50 0.89% | 162 70.78% | ||||
book value per share | -0.26 - | -1.02 292.14% | 6.08 694.17% | 1.74 71.35% | 0.66 61.99% | ||
capex per share | |||||||
capex to depreciation | |||||||
capex to operating cash flow | |||||||
capex to revenue | |||||||
cash per share | 0.01 - | 0.06 930.39% | 6.05 9,345.85% | 1.68 72.19% | 0.64 62.23% | ||
days of inventory on hand | |||||||
days payables outstanding | |||||||
days sales outstanding | |||||||
debt to assets | 11.51 - | ||||||
debt to equity | -0.74 - | ||||||
dividend yield | |||||||
earnings yield | -0.03 - | -0.03 31.00% | -0.28 715.51% | -0.37 33.84% | -4.66 1,145.76% | -0.49 89.48% | |
enterprise value | 80.72M - | 84.08M 4.16% | 7.21M 91.43% | 28.64M 297.40% | -4.42M 115.43% | 10.80M 344.35% | |
enterprise value over ebitda | -41.15 - | -38.59 6.22% | -0.72 98.13% | -1.83 154.21% | 0.36 119.60% | -1.98 652.48% | |
ev to operating cash flow | -67.50 - | -40.19 40.46% | -1.85 95.40% | -1.83 1.34% | 0.39 121.11% | -2.22 675.34% | |
ev to sales | |||||||
free cash flow per share | -0.25 - | -0.43 74.94% | -0.79 82.61% | -1.88 138.26% | -1.04 45.00% | -0.26 74.96% | |
free cash flow yield | -0.01 - | -0.03 74.94% | -0.11 306.32% | -0.37 249.48% | -4.39 1,093.12% | -0.45 89.72% | |
graham net net | -0.27 - | -1.02 281.81% | 5.74 660.21% | 1.53 73.35% | 0.54 64.62% | ||
graham number | 1.60 - | 3.63 126.65% | 16.94 366.66% | 8.66 48.87% | 4.05 53.28% | ||
income quality | 0.57 - | 0.85 49.47% | 0.38 55.49% | 0.98 161.11% | 0.94 4.75% | 0.92 1.78% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | 0 | |
interest coverage | -12.90 - | -7.38 42.76% | -26.04 252.78% | -2.76K 10,489.48% | 182.52 106.62% | ||
interest debt per share | 0.03 - | 0.81 2,485.53% | 0.08 90.42% | 0.00 99.13% | -0.01 995.08% | ||
inventory turnover | |||||||
invested capital | -0.74 - | ||||||
market cap | 80.75M - | 80.75M 0.00% | 37.00M 54.18% | 42.65M 15.25% | 2.61M 93.87% | 10.80M 313.26% | |
net current asset value | -1.28M - | -4.94M 284.95% | 29.94M 705.78% | 14.50M 51.57% | 7.33M 49.48% | ||
net debt to ebitda | 0.02 - | -1.53 10,080.10% | 2.98 294.93% | 0.90 69.93% | 0.57 36.25% | ||
net income per share | -0.44 - | -0.57 31.00% | -2.10 266.52% | -1.92 8.75% | -1.10 42.58% | -0.28 74.37% | |
operating cash flow per share | -0.25 - | -0.43 74.94% | -0.79 82.61% | -1.88 138.26% | -1.04 45.00% | -0.26 74.96% | |
payables turnover | |||||||
receivables turnover | |||||||
research and ddevelopement to revenue | |||||||
return on tangible assets | -32.06 - | -8.76 72.66% | -0.33 96.25% | -1.01 207.73% | -1.46 43.85% | ||
revenue per share | |||||||
roe | 1.68 - | 0.56 66.59% | -0.35 161.69% | -1.10 218.50% | -1.66 51.05% | ||
roic | 1.67 - | 1.87 12.01% | -0.33 117.88% | -1.08 222.77% | -1.67 54.98% | ||
sales general and administrative to revenue | |||||||
shareholders equity per share | -0.26 - | -1.02 292.14% | 6.08 694.17% | 1.74 71.35% | 0.66 61.99% | ||
stock based compensation to revenue | |||||||
tangible asset value | -1.26M - | -4.94M 292.14% | 29.94M 705.78% | 14.50M 51.57% | 7.33M 49.48% | ||
tangible book value per share | -0.26 - | -1.02 292.14% | 6.08 694.17% | 1.74 71.35% | 0.66 61.99% | ||
working capital | -1.28M - | -1.30M 1.64% | 29.94M 2,394.38% | 14.50M 51.57% | 7.33M 49.48% |
All numbers in USD (except ratios and percentages)